Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN - Free Report) in a report released on Friday morning,Benzinga reports. The firm currently has a $35.00 price target on the stock.

Several other analysts have also recently commented on SLN. Morgan Stanley dropped their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group reduced their target price on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research report on Friday. Finally, BMO Capital Markets decreased their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Stock Performance

Silence Therapeutics stock traded down $0.26 on Friday, reaching $5.33. The company's stock had a trading volume of 77,781 shares, compared to its average volume of 304,971. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $22.47. The company has a market cap of $159.53 million, a price-to-earnings ratio of -3.39 and a beta of 1.41. The business's fifty day moving average price is $4.13 and its 200 day moving average price is $4.94.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. As a group, equities analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics during the fourth quarter worth $26,000. Barclays PLC increased its holdings in Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after purchasing an additional 2,793 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after purchasing an additional 6,098 shares during the period. Ameriprise Financial Inc. bought a new stake in shares of Silence Therapeutics in the fourth quarter valued at about $113,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Silence Therapeutics during the fourth quarter worth about $134,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.